Searched for: in-biosketch:true
person:frontj01
Author Response: A Prospective Study of Neurologic Disorders in Hospitalized Patients With COVID-19 in New York City [Comment]
Frontera, Jennifer A; Balcer, Laura; Galetta, Steven
PMID: 33723025
ISSN: 1526-632x
CID: 4819672
Author Response: A Prospective Study of Neurologic Disorders in Hospitalized Patients With COVID-19 in New York City [Comment]
Frontera, Jennifer A; Lewis, Ariane; Balcer, Laura; Galetta, Steven
PMID: 33723027
ISSN: 1526-632x
CID: 4819682
Risk Factors for Intracerebral Hemorrhage in Patients With Atrial Fibrillation on Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention
Paciaroni, Maurizio; Agnelli, Giancarlo; Giustozzi, Michela; Caso, Valeria; Toso, Elisabetta; Angelini, Filippo; Canavero, Isabella; Micieli, Giuseppe; Antonenko, Kateryna; Rocco, Alessandro; Diomedi, Marina; Katsanos, Aristeidis H; Shoamanesh, Ashkan; Giannopoulos, Sotirios; Ageno, Walter; Pegoraro, Samuela; Putaala, Jukka; Strbian, Daniel; Sallinen, Hanne; Mac Grory, Brian C; Furie, Karen L; Stretz, Christoph; Reznik, Michael E; Alberti, Andrea; Venti, Michele; Mosconi, Maria Giulia; Vedovati, Maria Cristina; Franco, Laura; Zepponi, Giorgia; Romoli, Michele; Zini, Andrea; Brancaleoni, Laura; Riva, Letizia; Silvestrelli, Giorgio; Ciccone, Alfonso; Zedde, Maria Luisa; Giorli, Elisa; Kosmidou, Maria; Ntais, Evangelos; Palaiodimou, Lina; Halvatsiotis, Panagiotis; Tassinari, Tiziana; Saia, Valentina; Ornello, Raffaele; Sacco, Simona; Bandini, Fabio; Mancuso, Michelangelo; Orlandi, Giovanni; Ferrari, Elena; Pezzini, Alessandro; Poli, Loris; Cappellari, Manuel; Forlivesi, Stefano; Rigatelli, Alberto; Yaghi, Shadi; Scher, Erica; Frontera, Jennifer A; Masotti, Luca; Grifoni, Elisa; Caliandro, Pietro; Zauli, Aurelia; Reale, Giuseppe; Marcheselli, Simona; Gasparro, Antonio; Terruso, Valeria; Arnao, Valentina; Aridon, Paolo; Abdul-Rahim, Azmil H; Dawson, Jesse; Saggese, Carlo Emanuele; Palmerini, Francesco; Doronin, Boris; Volodina, Vera; Toni, Danilo; Risitano, Angela; Schirinzi, Erika; Del Sette, Massimo; Lochner, Piergiorgio; Monaco, Serena; Mannino, Marina; Tassi, Rossana; Guideri, Francesca; Acampa, Maurizio; Martini, Giuseppe; Lotti, Enrico Maria; Padroni, Marina; Pantoni, Leonardo; Rosa, Silvia; Bertora, Pierluigi; Ntaios, George; Sagris, Dimitrios; Baldi, Antonio; D'Amore, Cataldo; Mumoli, Nicola; Porta, Cesare; Denti, Licia; Chiti, Alberto; Corea, Francesco; Acciarresi, Monica; Flomin, Yuriy; Popovic, Nemanja; Tsivgoulis, Georgios
BACKGROUND AND PURPOSE/OBJECTIVE:-VASc and HAS-BLED scores in the same setting. METHODS:-VASc and HAS-BLED scores there are some risk factors in common, several multivariable logistic regression models were performed to identify independent prespecified predictors for ICH events. RESULTS:-VASc scores performed poorly in predicting ICH with areas under the curves of 0.496 (95% CI, 0.468-0.525) and 0.530 (95% CI, 0.500-0.560), respectively. CONCLUSIONS:-VASc scores.
PMID: 33657853
ISSN: 1524-4628
CID: 4801602
Cerebrospinal fluid in COVID-19: A systematic review of the literature
Lewis, Ariane; Frontera, Jennifer; Placantonakis, Dimitris G; Lighter, Jennifer; Galetta, Steven; Balcer, Laura; Melmed, Kara R
OBJECTIVE:We sought to review the literature on cerebrospinal fluid (CSF) testing in patients with COVID-19 for evidence of viral neuroinvasion by SARS-CoV-2. METHODS:We performed a systematic review of Medline and Embase between December 1, 2019 and November 18, 2020 to identify case reports or series of patients who had COVID-19 diagnosed based on positive SARS-CoV-2 polymerase chain reaction (PCR) or serologic testing and had CSF testing due to a neurologic symptom. RESULTS:We identified 242 relevant documents which included 430 patients with COVID-19 who had acute neurological symptoms prompting CSF testing. Of those, 321 (75%) patients had symptoms that localized to the central nervous system (CNS). Of 304 patients whose CSF was tested for SARS-CoV-2 PCR, there were 17 (6%) whose test was positive, all of whom had symptoms that localized to the central nervous system (CNS). The majority (13/17, 76%) of these patients were admitted to the hospital because of neurological symptoms. Of 58 patients whose CSF was tested for SARS-CoV-2 antibody, 7 (12%) had positive antibodies with evidence of intrathecal synthesis, all of whom had symptoms that localized to the CNS. Of 132 patients who had oligoclonal bands evaluated, 3 (2%) had evidence of intrathecal antibody synthesis. Of 77 patients tested for autoimmune antibodies in the CSF, 4 (5%) had positive findings. CONCLUSION:Detection of SARS-CoV-2 in CSF via PCR or evaluation for intrathecal antibody synthesis appears to be rare. Most neurological complications associated with SARS- CoV-2 are unlikely to be related to direct viral neuroinvasion.
PMCID:7833669
PMID: 33561753
ISSN: 1878-5883
CID: 4799772
A Prospective Study of Neurologic Disorders in Hospitalized COVID-19 Patients in New York City
Frontera, Jennifer A; Sabadia, Sakinah; Lalchan, Rebecca; Fang, Taolin; Flusty, Brent; Millar-Vernetti, Patricio; Snyder, Thomas; Berger, Stephen; Yang, Dixon; Granger, Andre; Morgan, Nicole; Patel, Palak; Gutman, Josef; Melmed, Kara; Agarwal, Shashank; Bokhari, Matthew; Andino, Andres; Valdes, Eduard; Omari, Mirza; Kvernland, Alexandra; Lillemoe, Kaitlyn; Chou, Sherry H-Y; McNett, Molly; Helbok, Raimund; Mainali, Shraddha; Fink, Ericka L; Robertson, Courtney; Schober, Michelle; Suarez, Jose I; Ziai, Wendy; Menon, David; Friedman, Daniel; Friedman, David; Holmes, Manisha; Huang, Joshua; Thawani, Sujata; Howard, Jonathan; Abou-Fayssal, Nada; Krieger, Penina; Lewis, Ariane; Lord, Aaron S; Zhou, Ting; Kahn, D Ethan; Czeisler, Barry M; Torres, Jose; Yaghi, Shadi; Ishida, Koto; Scher, Erica; de Havenon, Adam; Placantonakis, Dimitris; Liu, Mengling; Wisniewski, Thomas; Troxel, Andrea B; Balcer, Laura; Galetta, Steven
OBJECTIVE:To determine the prevalence and associated mortality of well-defined neurologic diagnoses among COVID-19 patients, we prospectively followed hospitalized SARS-Cov-2 positive patients and recorded new neurologic disorders and hospital outcomes. METHODS:We conducted a prospective, multi-center, observational study of consecutive hospitalized adults in the NYC metropolitan area with laboratory-confirmed SARS-CoV-2 infection. The prevalence of new neurologic disorders (as diagnosed by a neurologist) was recorded and in-hospital mortality and discharge disposition were compared between COVID-19 patients with and without neurologic disorders. RESULTS:Of 4,491 COVID-19 patients hospitalized during the study timeframe, 606 (13.5%) developed a new neurologic disorder in a median of 2 days from COVID-19 symptom onset. The most common diagnoses were: toxic/metabolic encephalopathy (6.8%), seizure (1.6%), stroke (1.9%), and hypoxic/ischemic injury (1.4%). No patient had meningitis/encephalitis, or myelopathy/myelitis referable to SARS-CoV-2 infection and 18/18 CSF specimens were RT-PCR negative for SARS-CoV-2. Patients with neurologic disorders were more often older, male, white, hypertensive, diabetic, intubated, and had higher sequential organ failure assessment (SOFA) scores (all P<0.05). After adjusting for age, sex, SOFA-scores, intubation, past history, medical complications, medications and comfort-care-status, COVID-19 patients with neurologic disorders had increased risk of in-hospital mortality (Hazard Ratio[HR] 1.38, 95% CI 1.17-1.62, P<0.001) and decreased likelihood of discharge home (HR 0.72, 95% CI 0.63-0.85, P<0.001). CONCLUSIONS:Neurologic disorders were detected in 13.5% of COVID-19 patients and were associated with increased risk of in-hospital mortality and decreased likelihood of discharge home. Many observed neurologic disorders may be sequelae of severe systemic illness.
PMID: 33020166
ISSN: 1526-632x
CID: 4626712
Editorial: Neurological and Neuroscientific Evidence in Aged COVID-19 Patients [Editorial]
Frontera, Jennifer A; Wisniewski, Thomas
PMCID:8558619
PMID: 34733153
ISSN: 1663-4365
CID: 5038262
Prevalence and Predictors of Prolonged Cognitive and Psychological Symptoms Following COVID-19 in the United States
Frontera, Jennifer A; Lewis, Ariane; Melmed, Kara; Lin, Jessica; Kondziella, Daniel; Helbok, Raimund; Yaghi, Shadi; Meropol, Sharon; Wisniewski, Thomas; Balcer, Laura; Galetta, Steven L
Background/Objectives/UNASSIGNED:Little is known regarding the prevalence and predictors of prolonged cognitive and psychological symptoms of COVID-19 among community-dwellers. We aimed to quantitatively measure self-reported metrics of fatigue, cognitive dysfunction, anxiety, depression, and sleep and identify factors associated with these metrics among United States residents with or without COVID-19. Methods/UNASSIGNED:We solicited 1000 adult United States residents for an online survey conducted February 3-5, 2021 utilizing a commercial crowdsourcing community research platform. The platform curates eligible participants to approximate United States demographics by age, sex, and race proportions. COVID-19 was diagnosed by laboratory testing and/or by exposure to a known positive contact with subsequent typical symptoms. Prolonged COVID-19 was self-reported and coded for those with symptoms ≥ 1 month following initial diagnosis. The primary outcomes were NIH PROMIS/Neuro-QoL short-form T-scores for fatigue, cognitive dysfunction, anxiety, depression, and sleep compared among those with prolonged COVID-19 symptoms, COVID-19 without prolonged symptoms and COVID-19 negative subjects. Multivariable backwards step-wise logistic regression models were constructed to predict abnormal Neuro-QoL metrics. Results/UNASSIGNED:= 0.047), but there were no significant differences in quantitative measures of anxiety, depression, fatigue, or sleep. Conclusion/UNASSIGNED:Prolonged symptoms occurred in 25% of COVID-19 positive participants, and NeuroQoL cognitive dysfunction scores were significantly worse among COVID-19 positive subjects, even after accounting for demographic and stressor covariates. Fatigue, anxiety, depression, and sleep scores did not differ between COVID-19 positive and negative respondents.
PMCID:8326803
PMID: 34349633
ISSN: 1663-4365
CID: 5005972
Prior Stroke and Age Predict Acute Ischemic Stroke Among Hospitalized COVID-19 Patients: A Derivation and Validation Study
Peng, Teng J; Jasne, Adam S; Simonov, Michael; Abdelhakim, Safa; Kone, Gbambele; Cheng, Yee Kuang; Rethana, Melissa; Tarasaria, Karan; Herman, Alison L; Baker, Anna D; Yaghi, Shadi; Frontera, Jennifer A; Sansing, Lauren H; Falcone, Guido J; Spudich, Serena; Schindler, Joseph; Sheth, Kevin N; Sharma, Richa
PMCID:8524436
PMID: 34675873
ISSN: 1664-2295
CID: 5068162
Impact of COVID-19 on the hospitalization, treatment, and outcomes of intracerebral and subarachnoid hemorrhage in the United States
Ravindra, Vijay M; Grandhi, Ramesh; Delic, Alen; Hohmann, Samuel; Shippey, Ernie; Tirschwell, David; Frontera, Jennifer A; Yaghi, Shadi; Majersik, Jennifer J; Anadani, Mohammad; de Havenon, Adam
OBJECTIVE:To examine the outcomes of adult patients with spontaneous intracranial and subarachnoid hemorrhage diagnosed with comorbid COVID-19 infection in a large, geographically diverse cohort. METHODS:We performed a retrospective analysis using the Vizient Clinical Data Base. We separately compared two cohorts of patients with COVID-19 admitted April 1-October 31, 2020-patients with intracerebral hemorrhage (ICH) and those with subarachnoid hemorrhage (SAH)-with control patients with ICH or SAH who did not have COVID-19 admitted at the same hospitals in 2019. The primary outcome was in-hospital death. Favorable discharge and length of hospital and intensive-care stay were the secondary outcomes. We fit multivariate mixed-effects logistic regression models to our outcomes. RESULTS:There were 559 ICH-COVID patients and 23,378 ICH controls from 194 hospitals. In the ICH-COVID cohort versus controls, there was a significantly higher proportion of Hispanic patients (24.5% vs. 8.9%), Black patients (23.3% vs. 20.9%), nonsmokers (11.5% vs. 3.2%), obesity (31.3% vs. 13.5%), and diabetes (43.4% vs. 28.5%), and patients had a longer hospital stay (21.6 vs. 10.5 days), a longer intensive-care stay (16.5 vs. 6.0 days), and a higher in-hospital death rate (46.5% vs. 18.0%). Patients with ICH-COVID had an adjusted odds ratio (aOR) of 2.43 [1.96-3.00] for the outcome of death and an aOR of 0.55 [0.44-0.68] for favorable discharge. There were 212 SAH-COVID patients and 5,029 controls from 119 hospitals. The hospital (26.9 vs. 13.4 days) and intensive-care (21.9 vs. 9.6 days) length of stays and in-hospital death rate (42.9% vs. 14.8%) were higher in the SAH-COVID cohort compared with controls. Patients with SAH-COVID had an aOR of 1.81 [1.26-2.59] for an outcome of death and an aOR of 0.54 [0.37-0.78] for favorable discharge. CONCLUSIONS:Patients with spontaneous ICH or SAH and comorbid COVID infection were more likely to be a racial or ethnic minority, diabetic, and obese and to have higher rates of death and longer hospital length of stay when compared with controls.
PMCID:8046225
PMID: 33852591
ISSN: 1932-6203
CID: 4846102
Impact of COVID-19 on Outcomes in Ischemic Stroke Patients in the United States
de Havenon, Adam; Ney, John P; Callaghan, Brian; Delic, Alen; Hohmann, Samuel; Shippey, Ernie; Esper, Gregory J; Stulberg, Eric; Tirschwell, David; Frontera, Jennifer; Yaghi, Shadi; Anadani, Mohammad; Majersik, Jennifer J
BACKGROUND:Studies have shown worse outcomes in patients with comorbid ischemic stroke (IS) and coronavirus disease 2019 (COVID-19), but have had small sample sizes. METHODS:We retrospectively identified patients in the Vizient Clinical Data Base® with IS as a discharge diagnosis. The study outcomes were in-hospital death and favorable discharge (home or acute rehabilitation). In the primary analysis, we compared IS patients with laboratory-confirmed COVID-19 (IS-COVID) discharged April 1-July 31, 2020 to pre-COVID IS patients discharged in 2019 (IS controls). In a secondary analysis, we compared a matched cohort of IS-COVID patients to patients within the IS controls who had pneumonia (IS-PNA), created with inverse-probability-weighting (IPW). RESULTS:In the primary analysis, we included 166,586 IS controls and 2086 IS-COVID from 312 hospitals in 46 states. Compared to IS controls, IS-COVID were less likely to have hypertension, dyslipidemia, or be smokers, but more likely to be male, younger, have diabetes, obesity, acute renal failure, acute coronary syndrome, venous thromboembolism, intubation, and comorbid intracerebral or subarachnoid hemorrhage (all p<0.05). Black and Hispanic patients accounted for 21.7% and 7.4% of IS controls, respectively, but 33.7% and 18.5% of IS-COVID (p<0.001). IS-COVID, versus IS controls, were less likely to receive alteplase (1.8% vs 5.6%, p<0.001), mechanical thrombectomy (4.4% vs. 6.7%, p<0.001), to have favorable discharge (33.9% vs. 66.4%, p<0.001), but more likely to die (30.4% vs. 6.5%, p<0.001). In the matched cohort of patients with IS-COVID and IS-PNA, IS-COVID had a higher risk of death (IPW-weighted OR 1.56, 95% CI 1.33-1.82) and lower odds of favorable discharge (IPW-weighted OR 0.63, 95% CI 0.54-0.73). CONCLUSIONS:Ischemic stroke patients with COVID-19 are more likely to be male, younger, and Black or Hispanic, with significant increases in morbidity and mortality compared to both ischemic stroke controls from 2019 and to patients with ischemic stroke and pneumonia.
PMID: 33310595
ISSN: 1532-8511
CID: 4717442